{Reference Type}: Journal Article
{Title}: Recommendations on the treatment of metastatic hormone-sensitive prostate cancer: Patient selection.
{Author}: Borque-Fernando Á;Zapatero A;Manneh R;Alonso-Gordoa T;Couñago F;Domínguez-Esteban M;López-Valcárcel M;Rodríguez-Antolín A;Sala-González N;Sanmamed N;Maroto P; ;
{Journal}: Actas Urol Esp (Engl Ed)
{Volume}: 0
{Issue}: 0
{Year}: 2024 May 11
暂无{DOI}: 10.1016/j.acuroe.2024.05.008
{Abstract}: The standard treatment for metastatic hormone-sensitive prostate cancer (mHSPC) is now a combination of androgen deprivation therapy plus an androgen receptor-targeted therapy (abiraterone, apalutamide, enzalutamide or darolutamide), with or without chemotherapy (docetaxel). The selection of suitable patients for each therapeutic approach has become a determining factor to ensure efficacy and minimize side effects. This article combines recent clinical evidence with the accumulated experience of experts in medical oncology, radiation oncology and urology, to provide a comprehensive view and therapeutic recommendations for mHSPC.